Kairos Pharma to Present Promising Phase 2 Prostate Cancer Data Highlighting Carotuximab’s Potential to Overcome Hormone Therapy Resistance at ESMO 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics that address treatment…
Bimiralisib Topical PI3K/mTOR Inhibitor Demonstrates Up to 92% Clearance and Excellent Tolerability in Phase 2 Actinic Keratosis Trial Torqur AG, a clinical-stage biopharmaceutical company and a subsidiary of the Swiss Rockets AG incubator, has announced highly encouraging results from its…
CareDx Unveils New IVDR-Certified Transplant Diagnostics and Advanced HLA Typing Technologies at ASHI 2025 CareDx, Inc. widely recognized as The Transplant Company™ — announced a major wave of product innovations and regulatory milestones during the American Society for Histocompatibility and…
Global Lymphoma Antibody Drug Conjugates Market 2030: Pipeline, Patents, Prices, Approved Sales, and Clinical Trial Insights Lymphoma Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030”, providing an in-depth analysis of the evolving landscape…
Alnylam Pharmaceuticals Reports HELIOS-B Phase 3 Findings: Vutrisiran Reduces Gastrointestinal Events in ATTR-CM Patients Alnylam Pharmaceuticals, Inc. , a global leader in RNA interference (RNAi) therapeutics, today unveiled new analyses from the HELIOS-B Phase 3 study evaluating AMVUTTRA® (vutrisiran). Vutrisiran…
International Day of Older Persons: AOP Health Brings Urgent Attention to the Silent Burden of Venous Leg Ulcers Every year on October 1, the world observes the United Nations’ International Day of Older Persons, a moment dedicated to honoring the…
Quince Therapeutics Publishes Advanced Population PK Modeling Study of eDSP in Pediatric Ataxia-Telangiectasia Patients in CPT: Pharmacometrics & Systems Pharmacology Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company pioneering patient-specific therapies for rare diseases, has announced the publication of…
TAE Life Sciences and University of Wisconsin–Madison Collaborate to Bring Revolutionary Accelerator-Based BNCT Cancer Therapy to the U.S. TAE Life Sciences (TLS), a global innovator in the field of advanced cancer therapies, has joined forces with the University of Wisconsin–Madison…
Potential First Approved Treatment in the EU Targeting NF1-Associated Plexiform Neurofibromas koselugo (selumetinib), an oral, selective MEK inhibitor, has been recommended for approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with…
CHMP Recommends EU Approval of Tezspire for Chronic Rhinosinusitis with Nasal Polyps AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The Committee…
Merck Secures Dual Positive CHMP Opinions for KEYTRUDA® in Europe: Subcutaneous Administration and New Head & Neck Cancer Indication Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced a major regulatory milestone in Europe as…
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) to treat post-partum…
